Corcept Therapeutics Incorporated (CORT)
USD 72.77
(1.8%)
USD 72.77
(1.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 106.14 Million USD | 4.66% |
| 2022 | 101.41 Million USD | -9.86% |
| 2021 | 112.51 Million USD | 6.13% |
| 2020 | 106.01 Million USD | 12.56% |
| 2019 | 94.18 Million USD | 24.89% |
| 2018 | 75.41 Million USD | -41.6% |
| 2017 | 129.12 Million USD | 1486.27% |
| 2016 | 8.14 Million USD | 227.03% |
| 2015 | -6.4 Million USD | 79.58% |
| 2014 | -31.38 Million USD | 31.79% |
| 2013 | -46.01 Million USD | -20.93% |
| 2012 | -38.04 Million USD | -17.6% |
| 2011 | -32.35 Million USD | -24.6% |
| 2010 | -25.96 Million USD | -28.76% |
| 2009 | -20.16 Million USD | -0.52% |
| 2008 | -20.06 Million USD | -73.34% |
| 2007 | -11.57 Million USD | 53.47% |
| 2006 | -24.87 Million USD | -23.79% |
| 2005 | -20.09 Million USD | -29.34% |
| 2004 | -15.53 Million USD | -58.32% |
| 2003 | -9.81 Million USD | 46.97% |
| 2002 | -18.5 Million USD | -148.24% |
| 2001 | -7.45 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 27.76 Million USD | -11.46% |
| 2024 Q2 | 35.48 Million USD | 27.83% |
| 2024 Q3 | 47.21 Million USD | 31.57% |
| 2023 Q2 | 27.52 Million USD | 73.36% |
| 2023 Q4 | 31.35 Million USD | -0.07% |
| 2023 FY | 106.14 Million USD | 4.66% |
| 2023 Q1 | 15.87 Million USD | -4.35% |
| 2023 Q3 | 31.37 Million USD | 13.99% |
| 2022 Q4 | 16.6 Million USD | -52.03% |
| 2022 Q3 | 34.6 Million USD | 26.25% |
| 2022 Q2 | 27.41 Million USD | 20.24% |
| 2022 FY | 101.41 Million USD | -9.86% |
| 2022 Q1 | 22.79 Million USD | -28.88% |
| 2021 FY | 112.51 Million USD | 6.13% |
| 2021 Q2 | 26.52 Million USD | 13.03% |
| 2021 Q4 | 32.05 Million USD | 5.19% |
| 2021 Q1 | 23.46 Million USD | -9.73% |
| 2021 Q3 | 30.47 Million USD | 14.89% |
| 2020 Q2 | 28.32 Million USD | -5.78% |
| 2020 FY | 106.01 Million USD | 12.56% |
| 2020 Q1 | 30.06 Million USD | 2.33% |
| 2020 Q3 | 21.62 Million USD | -23.66% |
| 2020 Q4 | 25.99 Million USD | 20.2% |
| 2019 Q4 | 29.38 Million USD | 11.55% |
| 2019 Q3 | 26.34 Million USD | 30.49% |
| 2019 FY | 94.18 Million USD | 24.89% |
| 2019 Q2 | 20.18 Million USD | 10.46% |
| 2019 Q1 | 18.27 Million USD | -16.97% |
| 2018 Q3 | 17.74 Million USD | -2.47% |
| 2018 Q4 | 22 Million USD | 24.01% |
| 2018 FY | 75.41 Million USD | -41.6% |
| 2018 Q1 | 17.45 Million USD | -82.24% |
| 2018 Q2 | 18.19 Million USD | 4.22% |
| 2017 Q3 | 13.75 Million USD | 8.78% |
| 2017 Q4 | 98.33 Million USD | 614.76% |
| 2017 FY | 129.12 Million USD | 1486.27% |
| 2017 Q1 | 4.38 Million USD | -4.55% |
| 2017 Q2 | 12.64 Million USD | 188.22% |
| 2016 Q2 | 977 Thousand USD | 5242.11% |
| 2016 Q1 | -19 Thousand USD | -101.98% |
| 2016 FY | 8.14 Million USD | 227.03% |
| 2016 Q4 | 4.59 Million USD | 77.83% |
| 2016 Q3 | 2.58 Million USD | 164.59% |
| 2015 Q3 | -601 Thousand USD | 68.96% |
| 2015 FY | -6.4 Million USD | 79.58% |
| 2015 Q4 | 959 Thousand USD | 259.57% |
| 2015 Q2 | -1.93 Million USD | 59.92% |
| 2015 Q1 | -4.83 Million USD | -24.01% |
| 2014 Q4 | -3.89 Million USD | 35.15% |
| 2014 FY | -31.38 Million USD | 31.79% |
| 2014 Q1 | -13.93 Million USD | -25.22% |
| 2014 Q2 | -7.55 Million USD | 45.79% |
| 2014 Q3 | -6 Million USD | 20.47% |
| 2013 Q3 | -10.9 Million USD | 8.33% |
| 2013 Q1 | -12.08 Million USD | -8.63% |
| 2013 FY | -46.01 Million USD | -20.93% |
| 2013 Q4 | -11.12 Million USD | -2.0% |
| 2013 Q2 | -11.89 Million USD | 1.55% |
| 2012 Q1 | -11.03 Million USD | -11.05% |
| 2012 Q4 | -11.12 Million USD | -34.14% |
| 2012 Q3 | -8.29 Million USD | -9.16% |
| 2012 FY | -38.04 Million USD | -17.6% |
| 2012 Q2 | -7.59 Million USD | 31.15% |
| 2011 Q2 | -8.88 Million USD | -25.08% |
| 2011 Q3 | -6.43 Million USD | 27.55% |
| 2011 FY | -32.35 Million USD | -24.6% |
| 2011 Q4 | -9.93 Million USD | -54.41% |
| 2011 Q1 | -7.1 Million USD | -0.11% |
| 2010 Q2 | -5.69 Million USD | 6.22% |
| 2010 Q4 | -7.09 Million USD | 0.15% |
| 2010 FY | -25.96 Million USD | -28.76% |
| 2010 Q3 | -7.1 Million USD | -24.74% |
| 2010 Q1 | -6.07 Million USD | -17.47% |
| 2009 Q3 | -4.66 Million USD | 4.31% |
| 2009 Q1 | -5.45 Million USD | 11.68% |
| 2009 FY | -20.16 Million USD | -0.52% |
| 2009 Q4 | -5.17 Million USD | -10.75% |
| 2009 Q2 | -4.87 Million USD | 10.5% |
| 2008 FY | -20.06 Million USD | -73.34% |
| 2008 Q4 | -6.17 Million USD | -10.89% |
| 2008 Q3 | -5.56 Million USD | -26.59% |
| 2008 Q1 | -3.93 Million USD | 6.27% |
| 2008 Q2 | -4.39 Million USD | -11.86% |
| 2007 Q1 | -2.53 Million USD | 34.61% |
| 2007 Q2 | -1.41 Million USD | 44.1% |
| 2007 Q3 | -3.42 Million USD | -141.92% |
| 2007 FY | -11.57 Million USD | 53.47% |
| 2007 Q4 | -4.19 Million USD | -22.32% |
| 2006 Q1 | -6.73 Million USD | -28.26% |
| 2006 Q4 | -3.87 Million USD | 39.45% |
| 2006 Q3 | -6.4 Million USD | 18.58% |
| 2006 Q2 | -7.86 Million USD | -16.85% |
| 2006 FY | -24.87 Million USD | -23.79% |
| 2005 Q1 | -5.51 Million USD | -3.78% |
| 2005 Q3 | -5.22 Million USD | -27.05% |
| 2005 Q4 | -5.24 Million USD | -0.46% |
| 2005 FY | -20.09 Million USD | -29.34% |
| 2005 Q2 | -4.11 Million USD | 25.42% |
| 2004 Q4 | -5.31 Million USD | -29.89% |
| 2004 Q1 | -2.55 Million USD | -28.22% |
| 2004 Q3 | -4.08 Million USD | -14.09% |
| 2004 FY | -15.53 Million USD | -58.32% |
| 2004 Q2 | -3.58 Million USD | -40.49% |
| 2003 Q3 | -2.12 Million USD | 26.1% |
| 2003 Q2 | -2.88 Million USD | -2.49% |
| 2003 FY | -9.81 Million USD | 46.97% |
| 2003 Q1 | -2.81 Million USD | 0.0% |
| 2003 Q4 | -1.98 Million USD | 6.57% |
| 2002 FY | -18.5 Million USD | -148.24% |
| 2001 FY | -7.45 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 141.167% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 193.962% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 11439.744% |
| Autolus Therapeutics plc | -208.38 Million USD | 150.935% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 1293.684% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 465.144% |
| Shattuck Labs, Inc. | -87.29 Million USD | 221.584% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 185.15% |
| CervoMed Inc. | -2.17 Million USD | 4987.026% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 143.217% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 337.964% |
| Aptose Biosciences Inc. | -51.2 Million USD | 307.276% |
| Precision BioSciences, Inc. | -61.31 Million USD | 273.095% |
| Dyadic International, Inc. | -6.79 Million USD | 1661.925% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 218.967% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 1107.212% |
| Nektar Therapeutics | -276.05 Million USD | 138.449% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 18753.779% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 473.049% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 249.926% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 230.371% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 147.121% |
| GRI Bio, Inc. | -13.03 Million USD | 914.144% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 2667.13% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 185.539% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 1150.163% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 307.471% |
| IGM Biosciences, Inc. | -246.41 Million USD | 143.074% |
| INmune Bio, Inc. | -30 Million USD | 453.706% |
| Opthea Limited | -220.24 Million USD | 148.192% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 277.834% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 208.942% |
| Verastem, Inc. | -87.36 Million USD | 221.488% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 295.874% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 165.788% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 190.984% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -103.513% |
| NextCure, Inc. | -62.72 Million USD | 269.22% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 657.784% |
| Organovo Holdings, Inc. | -14.67 Million USD | 823.468% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 2186.483% |
| Arvinas, Inc. | -367.3 Million USD | 128.897% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 302.793% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 494.016% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 412.452% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 170.252% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 457.073% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 164.494% |
| Senti Biosciences, Inc. | -92.91 Million USD | 214.229% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 1118.843% |
| Apollomics, Inc. | -172.6 Million USD | 161.494% |
| PureTech Health plc | -65.69 Million USD | 261.56% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 368.852% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 244.709% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 172.223% |
| Synaptogenix, Inc. | -6.03 Million USD | 1857.72% |
| ChromaDex Corporation | -4.93 Million USD | 2249.453% |
| Beam Therapeutics Inc. | -132.52 Million USD | 180.089% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 1363.241% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 304.41% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 173.735% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 120.078% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 1461.696% |
| Gritstone bio, Inc. | -138.49 Million USD | 176.641% |
| Mesoblast Limited | -87.95 Million USD | 220.674% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 798.772% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 270.492% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 165.955% |
| MediWound Ltd. | -6.71 Million USD | 1680.405% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 159.279% |
| Fortress Biotech, Inc. | -60.63 Million USD | 275.042% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 237.681% |
| Achilles Therapeutics plc | -69.66 Million USD | 252.358% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 193.331% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 304.718% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 452.695% |
| Zai Lab Limited | -334.62 Million USD | 131.72% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 1964.067% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 145.237% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -4130.371% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 178.106% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 1482.833% |
| FibroGen, Inc. | -284.23 Million USD | 137.343% |
| Celcuity Inc. | -63.77 Million USD | 266.418% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 504.62% |
| ContextLogic Inc. | -317 Million USD | 133.483% |
| GH Research PLC | -35.58 Million USD | 398.255% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 230.105% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 570.583% |
| ImmuCell Corporation | -5.77 Million USD | 1938.05% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -115.421% |
| Amarin Corporation plc | -59.11 Million USD | 279.557% |
| TG Therapeutics, Inc. | 12.67 Million USD | -737.595% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 709.615% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 264.647% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 207.837% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 595.356% |
| Aptorum Group Limited | -2.82 Million USD | 3857.638% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 117.496% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 146.853% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 538.215% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 151.706% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 672.304% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 190.875% |
| Ardelyx, Inc. | -66.06 Million USD | 260.655% |
| Ainos, Inc. | -13.77 Million USD | 870.775% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 269.336% |
| Prothena Corporation plc | -147.02 Million USD | 172.19% |
| HilleVax, Inc. | -123.56 Million USD | 185.897% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 193.211% |
| Celularity Inc. | -196.29 Million USD | 154.072% |
| Rallybio Corporation | -74.56 Million USD | 242.348% |
| Cue Biopharma, Inc. | -50.73 Million USD | 309.213% |
| Omeros Corporation | -117.81 Million USD | 190.092% |
| Humacyte, Inc. | -110.77 Million USD | 195.815% |
| Immunocore Holdings plc | -55.28 Million USD | 291.98% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 690.191% |
| Blueprint Medicines Corporation | -506.98 Million USD | 120.936% |
| IO Biotech, Inc. | -86.08 Million USD | 223.3% |
| MEI Pharma, Inc. | 17.77 Million USD | -497.03% |
| GT Biopharma, Inc. | -7.59 Million USD | 1497.13% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 256.838% |
| Summit Therapeutics Inc. | -614.92 Million USD | 117.261% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 402.049% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 175.061% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 164.021% |
| Pulmatrix, Inc. | -14.12 Million USD | 851.646% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 401.577% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 204.916% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 228.44% |
| Acelyrin, Inc. | -381.64 Million USD | 127.811% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 122.058% |
| Cytokinetics, Incorporated | -526.24 Million USD | 120.169% |
| Vor Biopharma Inc. | -117.86 Million USD | 190.054% |
| Evogene Ltd. | -23.87 Million USD | 544.491% |
| Replimune Group, Inc. | -215.79 Million USD | 149.186% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 188.625% |
| PDS Biotechnology Corporation | -42.94 Million USD | 347.169% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 1452.896% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 116.502% |
| AEON Biopharma, Inc. | -52.55 Million USD | 301.956% |
| BioLineRx Ltd. | -60.61 Million USD | 275.108% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 358.462% |
| Atai Life Sciences N.V. | -40.22 Million USD | 363.872% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 240.544% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 461.488% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 136.326% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 480.758% |
| MediciNova, Inc. | -8.57 Million USD | 1338.287% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 186.099% |
| MiMedx Group, Inc. | 67.43 Million USD | -57.387% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 1367.066% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 144.366% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 116.939% |
| Mereo BioPharma Group plc | -29.46 Million USD | 460.212% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 150.697% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 452.04% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 144.987% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 2315.188% |
| Allakos Inc. | -185.7 Million USD | 157.156% |
| scPharmaceuticals Inc. | -54.81 Million USD | 293.651% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 209.046% |
| NLS Pharmaceutics AG | -12.17 Million USD | 971.999% |
| Precigen, Inc. | -95.9 Million USD | 210.673% |
| XOMA Corporation | -40.83 Million USD | 359.95% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 204.192% |
| Incyte Corporation | 597.59 Million USD | 82.239% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 1166.975% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 189.56% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 221.055% |
| Seer, Inc. | -86.27 Million USD | 223.022% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 536.085% |
| CRISPR Therapeutics AG | -153.61 Million USD | 169.097% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 169.94% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 402.23% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 1411.676% |
| Akari Therapeutics, Plc | -10 Million USD | 1160.552% |
| Novavax, Inc. | -545.06 Million USD | 119.473% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 1692.522% |
| UroGen Pharma Ltd. | -102.24 Million USD | 203.81% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 199.389% |
| Entera Bio Ltd. | -8.88 Million USD | 1294.06% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 609.309% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 201.376% |
| Chimerix, Inc. | -82.09 Million USD | 229.289% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 237.153% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 152.651% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 279.951% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 74.414% |
| AnaptysBio, Inc. | -163.61 Million USD | 164.87% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 842.926% |
| Portage Biotech Inc. | -75.33 Million USD | 240.883% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 209.813% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 253.915% |
| OKYO Pharma Limited | -16.82 Thousand USD | 630929.707% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 891.073% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 1370.06% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 1054.366% |
| AbCellera Biologics Inc. | -146.39 Million USD | 172.501% |
| Genprex, Inc. | -30.86 Million USD | 443.935% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 144.989% |
| NLS Pharmaceutics AG | -12.17 Million USD | 971.999% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 2104.148% |
| Daré Bioscience, Inc. | -30.16 Million USD | 451.907% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 2005.908% |
| Bicycle Therapeutics plc | -180.66 Million USD | 158.75% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 124.324% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 234.431% |
| Erasca, Inc. | -125.04 Million USD | 184.883% |
| bluebird bio, Inc. | -211.91 Million USD | 150.087% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 532.465% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 36.688% |
| DBV Technologies S.A. | -72.72 Million USD | 245.945% |
| Fortress Biotech, Inc. | -60.63 Million USD | 275.042% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 150.014% |
| CorMedix Inc. | -46.33 Million USD | 329.05% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 195.279% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 411.252% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 316.083% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 321.499% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 175.048% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 148.309% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 155.163% |
| Onconetix, Inc. | -37.4 Million USD | 383.723% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 1162.888% |
| Prime Medicine, Inc. | -198.13 Million USD | 153.57% |
| Adagene Inc. | -18.94 Million USD | 660.213% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 143.976% |
| GlycoMimetics, Inc. | -36.89 Million USD | 387.647% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 189.172% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 153.052% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 19.791% |
| SciSparc Ltd. | -5.12 Million USD | 2172.237% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 88363.176% |
| Minerva Neurosciences, Inc. | -30 Million USD | 453.737% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 245.615% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -365.404% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 157753.175% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 140.49% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 855.666% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 124.109% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 1174.944% |
| 2seventy bio, Inc. | -217.57 Million USD | 148.784% |
| ADMA Biologics, Inc. | -28.23 Million USD | 475.863% |
| Clene Inc. | -49.5 Million USD | 314.407% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 576.23% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 314.711% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 132.353% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 426.154% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -367.165% |
| Absci Corporation | -110.56 Million USD | 195.997% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 97.315% |
| Surrozen, Inc. | -43.04 Million USD | 346.596% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 203.987% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 282.08% |
| Cingulate Inc. | -23.53 Million USD | 550.989% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 1635.59% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 1476.534% |
| Jaguar Health, Inc. | -41.3 Million USD | 356.998% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 217.659% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 273.188% |
| Kronos Bio, Inc. | -112.67 Million USD | 194.202% |
| Innoviva, Inc. | 179.72 Million USD | 40.942% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 253.388% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 1687.734% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 207.978% |
| Soligenix, Inc. | -6.14 Million USD | 1828.459% |
| AlloVir, Inc. | -190.41 Million USD | 155.741% |
| Century Therapeutics, Inc. | -136.67 Million USD | 177.66% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 205.405% |
| Kura Oncology, Inc. | -152.63 Million USD | 169.54% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -18670.227% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 247.626% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 589.847% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 384.253% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 196.003% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 351.554% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 764.969% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 771.986% |
| HCW Biologics Inc. | -24.99 Million USD | 524.657% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 180.11% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 138.439% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 144.617% |
| Lantern Pharma Inc. | -15.96 Million USD | 764.974% |
| Histogen Inc. | -10.62 Million USD | 1099.341% |
| Surrozen, Inc. | -43.04 Million USD | 346.596% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 363.205% |
| Kodiak Sciences Inc. | -260.49 Million USD | 140.746% |
| MoonLake Immunotherapeutics | -36 Million USD | 394.774% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 316.94% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 190.59% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 436.482% |
| Moderna, Inc. | -4.71 Billion USD | 102.252% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 128.977% |
| Turnstone Biologics Corp. | -55.2 Million USD | 292.283% |
| Immix Biopharma, Inc. | -15.42 Million USD | 788.057% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 754.862% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 236.042% |
| Exelixis, Inc. | 207.76 Million USD | 48.913% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 178.418% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 284.55% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 19939.252% |
| Alkermes plc | 355.75 Million USD | 70.165% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 264.647% |
| Arcellx, Inc. | -70.69 Million USD | 250.149% |
| ESSA Pharma Inc. | -26.58 Million USD | 499.288% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 2753.533% |
| Avid Bioservices, Inc. | -140.75 Million USD | 175.409% |
| Insmed Incorporated | -749.56 Million USD | 114.16% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 356.123% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 179.318% |
| Moolec Science SA | -51.78 Million USD | 304.947% |
| RenovoRx, Inc. | -10.23 Million USD | 1137.334% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 302.669% |
| Geron Corporation | -184.12 Million USD | 157.645% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 352.871% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 258.43% |
| Royalty Pharma plc | 1.13 Billion USD | 90.647% |
| OmniAb, Inc. | -50.61 Million USD | 309.684% |
| Alector, Inc. | -130.39 Million USD | 181.401% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 178.069% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 161.828% |
| Humacyte, Inc. | -110.77 Million USD | 195.815% |
| Structure Therapeutics Inc. | -89.62 Million USD | 218.433% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 132.761% |
| 89bio, Inc. | -142.18 Million USD | 174.647% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 1122.839% |
| Aura Biosciences, Inc. | -76.4 Million USD | 238.912% |
| Immunic, Inc. | -93.61 Million USD | 213.383% |
| Veracyte, Inc. | -74.4 Million USD | 242.654% |
| Genelux Corporation | -28.29 Million USD | 475.093% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 465.181% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 1615.876% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 663.594% |
| Immunovant, Inc. | -259.33 Million USD | 140.928% |
| Vericel Corporation | -3.18 Million USD | 3435.638% |
| Fortrea Holdings Inc. | -3.4 Million USD | 3221.765% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 183.81% |
| XBiotech Inc. | -24.55 Million USD | 532.219% |
| Agenus Inc. | -245.76 Million USD | 143.188% |
| Acasti Pharma Inc. | -12.85 Million USD | 925.799% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 948.177% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 572.619% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 764.969% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 292.307% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 255.505% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 951.163% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 576.658% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 459.906% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 489.676% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 157.473% |
| United Therapeutics Corporation | 984.8 Million USD | 89.222% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 2107.727% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 2315.188% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 2186.483% |
| Silo Pharma, Inc. | -3.7 Million USD | 2968.119% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 911.973% |
| Pharming Group N.V. | -10.54 Million USD | 1106.257% |
| XOMA Corporation | -40.83 Million USD | 359.95% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 536.085% |
| Bionomics Limited | -15.49 Billion USD | 100.685% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 464.029% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 243.841% |
| uniQure N.V. | -308.47 Million USD | 134.408% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 238.919% |
| Cassava Sciences, Inc. | -97.21 Million USD | 209.178% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 2918.598% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 623.089% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 185.992% |
| Pluri Inc. | -20.88 Million USD | 608.139% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 1394.121% |
| MeiraGTx Holdings plc | -84.02 Million USD | 226.317% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 562.867% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 706.301% |
| CalciMedica, Inc. | -34.35 Million USD | 408.933% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 137.472% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 170.021% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 846329.955% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 464.029% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 201.21% |
| Nutriband Inc. | -5.48 Million USD | 2034.985% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 362.593% |
| Compugen Ltd. | -18.75 Million USD | 665.959% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 97.559% |
| ProKidney Corp. | -35.46 Million USD | 399.256% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 2222.589% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 2567.502% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 204.321% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 231.605% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 330.494% |
| Benitec Biopharma Inc. | -21.75 Million USD | 587.978% |
| GeoVax Labs, Inc. | -25.96 Million USD | 508.753% |
| Biomea Fusion, Inc. | -117.25 Million USD | 190.521% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 169.299% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 205.259% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -653.621% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 576.819% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 131.329% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 155.006% |
| Imunon, Inc. | -19.51 Million USD | 643.89% |
| BioAtla, Inc. | -123.46 Million USD | 185.97% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 132.432% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 387.261% |
| Zura Bio Limited | -60.36 Million USD | 275.845% |
| aTyr Pharma, Inc. | -50.38 Million USD | 310.641% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 128.408% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 144.647% |
| Galecto, Inc. | -38.34 Million USD | 376.774% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 157753.175% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 62.307% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 159.926% |
| PolyPid Ltd. | -23.86 Million USD | 544.752% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 774.676% |
| Forte Biosciences, Inc. | -31.47 Million USD | 437.209% |
| Xencor, Inc. | -126.08 Million USD | 184.18% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 599.094% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 1692.522% |
| Instil Bio, Inc. | -156.08 Million USD | 168.001% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 1367.066% |
| OncoCyte Corporation | -27.78 Million USD | 482.06% |
| Elevation Oncology, Inc. | -45.7 Million USD | 332.234% |
| Purple Biotech Ltd. | -19.88 Million USD | 633.903% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 1612.181% |
| MacroGenics, Inc. | -9.05 Million USD | 1271.782% |
| Verona Pharma plc | -54.36 Million USD | 295.222% |
| Tharimmune, Inc. | -9.31 Million USD | 1238.952% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 226.38% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 206.228% |
| Aditxt, Inc. | -32.38 Million USD | 427.786% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 6056.229% |
| Savara Inc. | -54.69 Million USD | 294.047% |
| Curis, Inc. | -47.41 Million USD | 323.863% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 787.209% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 455.995% |
| BeiGene, Ltd. | -881.7 Million USD | 112.038% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 2222.589% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 364.313% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 897.086% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 275.763% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 523.02% |
| Adicet Bio, Inc. | -142.65 Million USD | 174.402% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1551.641% |
| Quantum-Si incorporated | -95.96 Million USD | 210.609% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 828.095% |
| Generation Bio Co. | -126.61 Million USD | 183.831% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 228.745% |
| Invivyd, Inc. | -198.64 Million USD | 153.433% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 131.038% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 1321.886% |
| Moolec Science SA | -51.78 Million USD | 304.947% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 426.735% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 295.031% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 207.438% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 166.005% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 117.257% |
| Evaxion Biotech A/S | -22.12 Million USD | 579.729% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 231.466% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 253.528% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 366.282% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 278.378% |
| Clearmind Medicine Inc. | -11.95 Million USD | 987.827% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 261.393% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -48.635% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 4185051.68% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 223.569% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 169.376% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 149.476% |
| ImmunityBio, Inc. | -583.19 Million USD | 118.2% |
| Korro Bio, Inc. | -81.17 Million USD | 230.759% |
| Kineta, Inc. | -14.09 Million USD | 852.819% |
| BioVie Inc. | -32.12 Million USD | 430.443% |
| Codexis, Inc. | -76.24 Million USD | 239.218% |
| Celularity Inc. | -196.29 Million USD | 154.072% |
| Virax Biolabs Group Limited | -6.73 Million USD | 1676.289% |
| Cibus, Inc. | -267.62 Million USD | 139.66% |
| Annexon, Inc. | -134.23 Million USD | 179.069% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 273.352% |
| Eyenovia, Inc. | -27.26 Million USD | 489.346% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -391.594% |
| NeurAxis, Inc. | -14.62 Million USD | 825.66% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 453.364% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 349.776% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 599.642% |
| Notable Labs, Ltd. | -11.26 Million USD | 1042.294% |
| IN8bio, Inc. | -30 Million USD | 453.717% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 647.65% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 210.574% |
| Lumos Pharma, Inc. | -34.03 Million USD | 411.865% |
| Liquidia Corporation | -78.5 Million USD | 235.207% |
| Mustang Bio, Inc. | -51.6 Million USD | 305.69% |
| Quantum-Si incorporated | -95.96 Million USD | 210.609% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 245.699% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 206.228% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 295.236% |
| 180 Life Sciences Corp. | -19.93 Million USD | 632.427% |
| Vaxcyte, Inc. | -402.26 Million USD | 126.386% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 158.193% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1551.641% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 227.95% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -3427.664% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 4185051.68% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 372.238% |
| PepGen Inc. | -78.62 Million USD | 234.994% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 456.545% |
| Solid Biosciences Inc. | -96.01 Million USD | 210.545% |
| Palisade Bio, Inc. | -12.3 Million USD | 962.927% |
| Nutriband Inc. | -5.48 Million USD | 2034.985% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 19939.252% |
| Immuneering Corporation | -53.47 Million USD | 298.498% |
| Belite Bio, Inc | -31.63 Million USD | 435.546% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 318.364% |
| GeoVax Labs, Inc. | -25.96 Million USD | 508.753% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 351.97% |
| Altimmune, Inc. | -88.44 Million USD | 220.004% |
| Peak Bio, Inc. | -1259.26 USD | 8428859.748% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 504.62% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 743.858% |
| Neurogene Inc. | -36.31 Million USD | 392.26% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 164.951% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 1348.559% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 208.144% |
| Sesen Bio, Inc. | -19.88 Million USD | 633.796% |
| argenx SE | -295.05 Million USD | 135.973% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 227.95% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 343.692% |
| Immunome, Inc. | -106.8 Million USD | 199.376% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 613919.439% |
| Design Therapeutics, Inc. | -66.86 Million USD | 258.745% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 380.186% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 248.273% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 123.903% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 195.137% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 178.554% |
| Athira Pharma, Inc. | -117.67 Million USD | 190.2% |
| XOMA Corporation | -40.83 Million USD | 359.95% |
| Merus N.V. | -154.93 Million USD | 168.504% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 438.187% |
| Rezolute, Inc. | -68.45 Million USD | 255.042% |
| Clene Inc. | -49.5 Million USD | 314.407% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 788.172% |
| BeyondSpring Inc. | -21.02 Million USD | 604.804% |
| Synlogic, Inc. | -57.28 Million USD | 285.294% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 991.858% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 1080.418% |
| Peak Bio, Inc. | -1259.26 USD | 8428859.748% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 384.04% |
| Krystal Biotech, Inc. | 10.93 Million USD | -870.911% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 174.172% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 132.648% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 2397.917% |
| MannKind Corporation | -11.93 Million USD | 989.094% |
| Ikena Oncology, Inc. | -68.16 Million USD | 255.708% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 605.068% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 214.211% |
| Gossamer Bio, Inc. | -179.81 Million USD | 159.027% |
| CohBar, Inc. | -11.96 Million USD | 987.301% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 511.587% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 452.04% |
| Legend Biotech Corporation | -518.25 Million USD | 120.48% |
| Mural Oncology plc | -207.44 Million USD | 151.165% |
| Disc Medicine, Inc. | -76.42 Million USD | 238.874% |
| Champions Oncology, Inc. | -7.27 Million USD | 1558.769% |
| REGENXBIO Inc. | -263.49 Million USD | 140.282% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 1100.087% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 323.429% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 379.437% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 205.967% |
| Vaxart, Inc. | -82.46 Million USD | 228.709% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -31701.009% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 382.72% |
| Cellectis S.A. | -101.05 Million USD | 205.028% |
| Longeveron Inc. | -21.41 Million USD | 595.68% |
| Repare Therapeutics Inc. | -93.79 Million USD | 213.16% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 119.803% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 249.138% |
| Revolution Medicines, Inc. | -436.36 Million USD | 124.324% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 1715.279% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 444.342% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 253.087% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 263.968% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 1181.847% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 97.068% |
| Denali Therapeutics Inc. | -145.22 Million USD | 173.087% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 88363.176% |
| Veru Inc. | -93.15 Million USD | 213.942% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 492.689% |
| Cingulate Inc. | -23.53 Million USD | 550.989% |
| Passage Bio, Inc. | -102.06 Million USD | 203.996% |
| Context Therapeutics Inc. | -23.96 Million USD | 542.91% |
| Exicure, Inc. | -16.91 Million USD | 727.527% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 156.183% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 381.061% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 1731.085% |
| Nuvalent, Inc. | -126.21 Million USD | 184.092% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 1109.352% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 222.17% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 447.499% |
| OmniAb, Inc. | -50.61 Million USD | 309.684% |
| Anew Medical, Inc. | 1.34 Million USD | -7784.855% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 761.514% |
| Lipocine Inc. | -16.35 Million USD | 749.092% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 259.864% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 266.69% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 351.554% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 321.277% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 635.223% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 119.602% |
| Ocugen, Inc. | -63.07 Million USD | 268.268% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 210.872% |
| Q32 Bio Inc. | -112.96 Million USD | 193.962% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 717.38% |
| Alumis Inc. Common Stock | -154.99 Million USD | 168.481% |
| Equillium, Inc. | -13.33 Million USD | 895.951% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 275.827% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 1428.77% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 663.04% |
| Dominari Holdings Inc. | -22.88 Million USD | 563.858% |
| Edesa Biotech, Inc. | -8.37 Million USD | 1367.432% |
| vTv Therapeutics Inc. | -20.25 Million USD | 624.148% |
| Bio-Techne Corporation | 168.1 Million USD | 36.861% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 130.146% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 17.627% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 187.12% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 379.765% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 194.228% |
| Nkarta, Inc. | -117.5 Million USD | 190.331% |
| BioCardia, Inc. | -11.57 Million USD | 1017.293% |
| Iterum Therapeutics plc | -38.37 Million USD | 376.615% |